C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor

Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non‐peptide antagonist

“…Therefore, we have now tested a second C-terminal fragment (NPY13-36) as well as the Y,-selective [Pro34]-NPY (Krstenansky et al, 1990 (Michel, 1991). Thus, we conclude that HEL cells express a homogeneous population of Y1-like NPY receptors.…”

Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226

“…This receptor is activated by the complete NPY molecule, PYY and the Yj agonists [Pro-']-NPY, [Leu31, Pro34]-NPY and [Leu31, Pro34]-PYY (Wahlestedt 'Author for correspondence. et al, 1986;Krstenansky et al, 1990;Fuhlendorff et al, 1990;Dumont et al, 1994). In contrast, the Y2 receptor seems to be located mainly prejunctionally and is activated by NPY, PYY and truncated C-terminal fragments of NPY and PYY (Wahlestedt et al, 1986;Grandt et al, 1994;Dumont et al, 1994).…”

Characterization of vascular neuropeptide Y receptors

“…In fact, on the latter receptor NPY 13-36 is only slightly less potent than NPY 1-36; a progressive N-terminal shortening of the molecule results in a gradual loss of potency . The Yl-type receptor seems to require the whole NPY molecule in order to become fully activated since C-terminal fragments are inactive or much less potent (Rioux et al, 1986;Wahlestedt et al, 1986). [Pro34]-NPY is a recently developed analogue that acts as a selective Y,-type receptor agonist (Krstenansky et al, 1990;Dumont et al, 1990). The gut hormone peptide YY (PYY) displays 70% homology with NPY and is about equipotent with NPY on either receptor subtype (Lundberg et al, 1982a;Wahlestedt et al, 1986;.…”